Biotech entity
Every one of those 1 sits in a single category, pharma. Karen Blomquist is most often covered alongside Albany International, which appears in 1 of these 1 story. Karen Blomquist appears in 1 tracked Biotech story from August 5, 2026.
Last mentioned: Aug 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Karen Blomquist is most often covered alongside Albany International, which appears in 1 of these 1 story. Karen Blomquist appears in 1 tracked Biotech story from August 5, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Karen Blomquist. Shared-story counts are live from our verified record — not editorial picks.
Albany International’s Q2 performance, with adjusted EBITDA margin expanding to 17.6% and record Engineered Composites growth, underscores precision manufacturing at scale—capabilities directly relevant to bioprocessing equipment supply.
Source: Motley Fool Transcribing (us) · fool.com
Karen Blomquist is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
